Effect of Pericardial Effusion on Right Ventricular Functions in Oncology Patients Receiving Chemotherapy

Basit Öğe Kaydı
dc.contributor.authorTatar, Sefa
dc.contributor.authorYavuz, Yunus Emre
dc.contributor.authorOktay, Irem
dc.contributor.authorAydin, Nergiz
dc.contributor.authorAlsancak, Yakup
dc.contributor.authorIcli, Abdullah
dc.date.accessioned2024-02-23T14:38:09Z
dc.date.available2024-02-23T14:38:09Z
dc.date.issued2023
dc.departmentNEÜen_US
dc.description.abstractIntroduction: Pericardial effusion is an indicator of poor prognosis in patients with cancer. We investigated the effect of pericardial effusion development on right ventricular function in oncology patients receiving chemotherapy for malignancy. Methods: A total of 90 patients who were followed up in the oncology clinic and who applied to our outpatient clinic for routine cardiac examination were included in the study. Echocardiography was performed on the patients, and they were divided into two groups: patients with and without pericardial effusion. Demographic characteristics and, clinical and laboratory findings of the patients were recorded. The right ventricular functions of the patients were then evaluated. Results: Pericardial effusion was in 30 (33.3%) of 90 patients included in the study. The mean age of patients without pericardial effusion was 57.33 +/- 15.59, and the mean age of patients with effusion was 60.27 +/- 13.51, and it was similar between the groups (p=0.36). No statistically significant difference was detected between the groups in right ventricular (RV) fractionated area change, RV-early peak, tricuspid annular plane systolic excursion, pulmonary artery pressure, E/E', and heart failure with preserved ejection fraction values, which are parameters that indicate right ventricular functions and diastolic dysfunction. However, RV systolic velocity and RV-AM, which are indicators of diastolic dysfunction, were found at higher rates in the patient group with pericardial effusion (p-value 0.041 and 0.001, respectively). In addition, Mitral E velocity was found to be lower in the patient group with pericardial effusion (p=0.032). Conclusion: In malignancy patients who develop pericardial effusion, we recommend that diastolic parameters be checked and close clinical follow-up of the patients be performed before overt heart failure clinic develops. It should be kept in mind that the development of pericardial effusion in oncology patients receiving chemotherapy does not mean right ventricular failure.en_US
dc.identifier.doi10.4274/imj.galenos.2023.02185
dc.identifier.endpage403en_US
dc.identifier.issn2619-9793
dc.identifier.issn2148-094X
dc.identifier.issue4en_US
dc.identifier.startpage399en_US
dc.identifier.urihttps://doi.org/10.4274/imj.galenos.2023.02185
dc.identifier.urihttps://hdl.handle.net/20.500.12452/16382
dc.identifier.volume24en_US
dc.identifier.wosWOS:001111211400014en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.language.isoenen_US
dc.publisherGalenos Publ Houseen_US
dc.relation.ispartofIstanbul Medical Journalen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectChemotherapyen_US
dc.subjectPericardial Effusionen_US
dc.subjectDiastolic Heart Failureen_US
dc.subjectRight Ventricular Failureen_US
dc.titleEffect of Pericardial Effusion on Right Ventricular Functions in Oncology Patients Receiving Chemotherapyen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu